SCHEMBL6260243

SCHEMBL6260243

N#CCCNC(=O)C1=CC(CF)(CF)Oc2ccc(C(F)(F)C(F)(F)F)cc21

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6270491 0.94
SCHEMBL8313859 0.93
SCHEMBL6269204 0.92 SCN9A (0.34) SCN9A
SCHEMBL6267682 0.88
SCHEMBL8432607 0.87 SCN9A (0.32) SCN9A
SCHEMBL8313695 0.84 KDM4E (0.34)
SCHEMBL8313504 0.84
SCHEMBL8314217 0.84
SCHEMBL8313718 0.84
SCHEMBL8316738 0.84 ABCC9 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0995438-B1 BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF PERIPHERAL VASCULAR DISEASE CHUGAI PHARMACEUTICAL CO LTD (JP) 2005-11-30 EP claimed
US-6248777-B1 VASCULAR DISORDERS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-06-19 US claimed
EP-0995438-A1 REMEDIES FOR PERIPHERAL CIRCULATION DISTURBANCES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-04-26 EP claimed
JP-10306026-A None JP disclosed
EP-0995438-B1 BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF PERIPHERAL VASCULAR DISEASE CHUGAI PHARMACEUTICAL CO LTD (JP) 2005-11-30 EP disclosed
EP-1004316-B1 THERAPEUTICS FOR DIABETIC COMPLICATIONS CHUGAI PHARMACEUTICAL CO LTD (JP) 2005-11-02 EP disclosed
US-20030065189-A1 Processes for producing 4-substituted benzopyran derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-04-03 US disclosed
US-6455708-B1 SUCH AS 2,2-BIS(FLUOROMETHYL)-N-(2-CYANOETHYL)-6-TRIFLUOROMETHYL-2H-1-BENZOPYRAN-4 -CARBOXAMIDE; USEFUL AS MEDICINES, AGRICHEMICALS AND COSMETICS, AND CHEMICAL INTERMEDIATES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-09-24 US disclosed
EP-1120412-A1 PROCESSES FOR THE PREPARATION OF 4-SUBSTITUTED BENZOPYRAN DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-08-01 EP disclosed
US-6248777-B1 VASCULAR DISORDERS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-06-19 US disclosed
US-6218411-B1 ADMINISTERING POTASSIUM CHANNEL ACTIVATOR FOR THERAPY OF DIABETIC COMPLICATION IN PATIENT SUFFERING FROM DIABETES MELLITUS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-04-17 US disclosed
EP-1004316-A1 REMEDIES FOR COMPLICATIONS OF DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-05-31 EP disclosed
EP-0995438-A1 REMEDIES FOR PERIPHERAL CIRCULATION DISTURBANCES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-04-26 EP disclosed
EP-0702952-B1 BENZOPYRAN DERIVATIVES CHUGAI PHARMACEUTICAL CO LTD (JP) 1999-12-08 EP disclosed
EP-0632033-B1 NOVEL BENZOPYRAN DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 1999-04-07 EP disclosed
JP-H10306026-A THERAPEUTIC AGENT FOR DISTURBANCES OF PERIPHERAL CIRCULATION CHUGAI PHARMACEUT CO LTD 1998-11-17 JP disclosed
US-5646308-A POTASSIUM CHANNEL ACTIVATORS USED AS ANTIASTHMATICS, ANTIEPILEPTICS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1997-07-08 US disclosed
US-5646310-A HYPOTENSIVE AGENTS, POTASSIUM CHANNEL ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1997-07-08 US disclosed
EP-0702952-A1 BENZOPYRAN DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 1996-03-27 EP disclosed
EP-0632033-A1 NOVEL BENZOPYRAN DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1995-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065189-A1 Processes for producing 4-substituted benzopyran derivatives CYP3A4, PARP14, BTD SCN9A 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.